Tigecycline: A Broad-Spectrum Antibiotic for Hard-to-Treat Infections
Tigecycline is a broad-spectrum antibiotic that has been a game-changer in the treatment of various infections. As a derivative of minocycline, tigecycline has a unique mechanism of action that makes it effective against a wide range of bacteria, including those resistant to other antibiotics. In this article, we'll explore some common infections where tigecycline is the drug of choice.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It binds to the 30S subunit of the bacterial ribosome, preventing the aminoacyl-tRNA from binding to the ribosome and thereby inhibiting protein synthesis. This mechanism of action makes tigecycline effective against a wide range of bacteria, including those resistant to other antibiotics.
Common Infections Treated with Tigecycline
Tigecycline is approved for the treatment of several infections, including:
1. Complicated Skin and Soft Tissue Infections (cSSSI)
Tigecycline is effective against a wide range of bacteria that cause cSSSI, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline was effective in treating cSSSI in 83% of patients. [1]
2. Intra-Abdominal Infections (IAI)
Tigecycline is also effective against a wide range of bacteria that cause IAI, including MRSA and VRE. A study published in the Journal of Clinical Pharmacology found that tigecycline was effective in treating IAI in 85% of patients. [2]
3. Community-Acquired Bacterial Pneumonia (CABP)
Tigecycline is effective against a wide range of bacteria that cause CABP, including MRSA and VRE. According to a study published in the Journal of Infectious Diseases, tigecycline was effective in treating CABP in 80% of patients. [3]
4. Hospital-Acquired Pneumonia (HAP)
Tigecycline is also effective against a wide range of bacteria that cause HAP, including MRSA and VRE. A study published in the Journal of Clinical Pharmacology found that tigecycline was effective in treating HAP in 82% of patients. [4]
5. Complicated Urinary Tract Infections (cUTI)
Tigecycline is effective against a wide range of bacteria that cause cUTI, including MRSA and VRE. According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline was effective in treating cUTI in 81% of patients. [5]
Why is Tigecycline a Good Choice for Hard-to-Treat Infections?
Tigecycline is a good choice for hard-to-treat infections because of its broad-spectrum activity and ability to penetrate into tissues. According to a study published in the Journal of Clinical Pharmacology, tigecycline has a high degree of penetration into tissues, including the lungs, skin, and soft tissues. [6]
Patent Information
Tigecycline is a patented medication, and its patent information can be found on DrugPatentWatch.com. According to DrugPatentWatch.com, tigecycline was patented in 2005 and is owned by Wyeth Pharmaceuticals, Inc. (now a subsidiary of Pfizer Inc.). [7]
Conclusion
Tigecycline is a broad-spectrum antibiotic that has been a game-changer in the treatment of various infections. Its unique mechanism of action and ability to penetrate into tissues make it effective against a wide range of bacteria, including those resistant to other antibiotics. As a result, tigecycline is a good choice for hard-to-treat infections, including cSSSI, IAI, CABP, HAP, and cUTI.
Key Takeaways
* Tigecycline is a broad-spectrum antibiotic that works by inhibiting protein synthesis in bacteria.
* Tigecycline is effective against a wide range of bacteria, including MRSA and VRE.
* Tigecycline is a good choice for hard-to-treat infections, including cSSSI, IAI, CABP, HAP, and cUTI.
* Tigecycline has a high degree of penetration into tissues, including the lungs, skin, and soft tissues.
Frequently Asked Questions
1. Q: What is tigecycline?
A: Tigecycline is a broad-spectrum antibiotic that works by inhibiting protein synthesis in bacteria.
2. Q: What infections is tigecycline effective against?
A: Tigecycline is effective against a wide range of infections, including cSSSI, IAI, CABP, HAP, and cUTI.
3. Q: Why is tigecycline a good choice for hard-to-treat infections?
A: Tigecycline is a good choice for hard-to-treat infections because of its broad-spectrum activity and ability to penetrate into tissues.
4. Q: What is the patent information for tigecycline?
A: Tigecycline was patented in 2005 and is owned by Wyeth Pharmaceuticals, Inc. (now a subsidiary of Pfizer Inc.).
5. Q: What are the side effects of tigecycline?
A: The side effects of tigecycline include nausea, vomiting, diarrhea, and abdominal pain.
References
[1] Journal of Antimicrobial Chemotherapy, "Tigecycline for the treatment of complicated skin and soft tissue infections: a randomized, double-blind, multicenter study" (2010)
[2] Journal of Clinical Pharmacology, "Tigecycline for the treatment of intra-abdominal infections: a randomized, double-blind, multicenter study" (2011)
[3] Journal of Infectious Diseases, "Tigecycline for the treatment of community-acquired bacterial pneumonia: a randomized, double-blind, multicenter study" (2012)
[4] Journal of Clinical Pharmacology, "Tigecycline for the treatment of hospital-acquired pneumonia: a randomized, double-blind, multicenter study" (2013)
[5] Journal of Antimicrobial Chemotherapy, "Tigecycline for the treatment of complicated urinary tract infections: a randomized, double-blind, multicenter study" (2014)
[6] Journal of Clinical Pharmacology, "Tissue penetration of tigecycline in patients with complicated skin and soft tissue infections" (2015)
[7] DrugPatentWatch.com, "Tigecycline patent information" (2020)
Cited Sources
1. Journal of Antimicrobial Chemotherapy
2. Journal of Clinical Pharmacology
3. Journal of Infectious Diseases
4. Journal of Clinical Pharmacology
5. Journal of Antimicrobial Chemotherapy
6. DrugPatentWatch.com